Cargando…

Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review

With the gradual development of immunotherapy for thyroid cancer, relevant research has increased. To better understand the current situation, development trend, evolution process, and research hotspots of this field, we conducted this comprehensive bibliometrics visual analysis. We retrieved papers...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Ran, Jiao, Hongguan, Piao, Yuanlin, Tian, Weiyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545358/
https://www.ncbi.nlm.nih.gov/pubmed/37773801
http://dx.doi.org/10.1097/MD.0000000000035506
_version_ 1785114654734811136
author Ding, Ran
Jiao, Hongguan
Piao, Yuanlin
Tian, Weiyi
author_facet Ding, Ran
Jiao, Hongguan
Piao, Yuanlin
Tian, Weiyi
author_sort Ding, Ran
collection PubMed
description With the gradual development of immunotherapy for thyroid cancer, relevant research has increased. To better understand the current situation, development trend, evolution process, and research hotspots of this field, we conducted this comprehensive bibliometrics visual analysis. We retrieved papers published from 1980 to 2022 from Web of Science Core Collection on January 31, 2023. CiteSpace, Pajek, VOSviewer, R-Bibliometrix, and Scimago Graphics are the tools to perform the analysis. Analysis methods mainly include co-occurrence analysis and cluster analysis. Analysis objects are countries or regions, institutions, authors, journals, and keywords, etc. In terms of publication number, the recent decade has witnessed rapid growth. USA was the most prolific country and has the most influence in the cooperation team. Sweden took the lead in focus on this research field and lasted for 21 years. Garden State Cancer Center was released most papers (28). INSERM played a major role in institutional cooperation. Goldenberg DM published the most papers (48), with H-Index 25 and G-Index 43. Journal of Nuclear Medicine has the greatest papers published (41). The average impactor factor of the top 10 journals is 7.2058. The top keywords with high burst strength are: radioimmunotherapy (14.85), monoclonal antibody (13.78), non hodgkins lymphoma (12.54). The research field of immunotherapy for thyroid cancer will be further developed. This study provides a valuable reference for future research in the field.
format Online
Article
Text
id pubmed-10545358
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-105453582023-10-03 Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review Ding, Ran Jiao, Hongguan Piao, Yuanlin Tian, Weiyi Medicine (Baltimore) 5700 With the gradual development of immunotherapy for thyroid cancer, relevant research has increased. To better understand the current situation, development trend, evolution process, and research hotspots of this field, we conducted this comprehensive bibliometrics visual analysis. We retrieved papers published from 1980 to 2022 from Web of Science Core Collection on January 31, 2023. CiteSpace, Pajek, VOSviewer, R-Bibliometrix, and Scimago Graphics are the tools to perform the analysis. Analysis methods mainly include co-occurrence analysis and cluster analysis. Analysis objects are countries or regions, institutions, authors, journals, and keywords, etc. In terms of publication number, the recent decade has witnessed rapid growth. USA was the most prolific country and has the most influence in the cooperation team. Sweden took the lead in focus on this research field and lasted for 21 years. Garden State Cancer Center was released most papers (28). INSERM played a major role in institutional cooperation. Goldenberg DM published the most papers (48), with H-Index 25 and G-Index 43. Journal of Nuclear Medicine has the greatest papers published (41). The average impactor factor of the top 10 journals is 7.2058. The top keywords with high burst strength are: radioimmunotherapy (14.85), monoclonal antibody (13.78), non hodgkins lymphoma (12.54). The research field of immunotherapy for thyroid cancer will be further developed. This study provides a valuable reference for future research in the field. Lippincott Williams & Wilkins 2023-09-29 /pmc/articles/PMC10545358/ /pubmed/37773801 http://dx.doi.org/10.1097/MD.0000000000035506 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 5700
Ding, Ran
Jiao, Hongguan
Piao, Yuanlin
Tian, Weiyi
Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review
title Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review
title_full Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review
title_fullStr Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review
title_full_unstemmed Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review
title_short Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review
title_sort knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: a review
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545358/
https://www.ncbi.nlm.nih.gov/pubmed/37773801
http://dx.doi.org/10.1097/MD.0000000000035506
work_keys_str_mv AT dingran knowledgemappingofimmunotherapyforthyroidcancerfrom1980to2022areview
AT jiaohongguan knowledgemappingofimmunotherapyforthyroidcancerfrom1980to2022areview
AT piaoyuanlin knowledgemappingofimmunotherapyforthyroidcancerfrom1980to2022areview
AT tianweiyi knowledgemappingofimmunotherapyforthyroidcancerfrom1980to2022areview